SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station's IPO is trending amid volatile price action, sparking debates about IPO allocations and the influence of retail investors. The community is weighing the long-term potential against concerns over reported losses and the overall crypto market sentiment, while also comparing it to other recent IPOs. Some traders express excitement about potential gains, while others are wary of the stock's high valuation and the involvement of the Winklevoss twins.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around aTyr Pharma as it approaches the topline Phase 3 data release for efzofitimod in pulmonary sarcoidosis, driving significant community discussion. While some traders are eyeing a potential pump and dump scenario, others are optimistic about the trial's outcome and future indications, highlighting strong institutional ownership and potential for a short squeeze. The community is closely monitoring for any data leaks and debating the influence of prominent figures on the stock's movement.

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Sonnet BioTherapeutics Holdings Inc

SONN is trending due to speculation surrounding a potential merger related to cryptocurrency, with community members pointing to a possible short squeeze given the stock's high short interest. Conversations revolve around predictions of a significant price increase and the potential impact of the merger on shareholder value. Some traders are actively shorting the stock, anticipating a price crash, while others remain bullish, drawing comparisons to similar stocks that have experienced substantial gains.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to reports suggesting the Trump administration may link COVID-19 vaccines to child deaths, sparking concerns about potential liabilities and renewed scrutiny of vaccine safety data. The community is debating the validity of the reports and the potential impact on vaccine manufacturers, while some investors see the dip as a buying opportunity for the high-dividend stock.  Others believe Pfizer is more than just a vaccine company and should be evaluated as a cancer treatment company.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending as traders anticipate the closing of its merger with Strive, potentially transforming it into a Bitcoin treasury company; high short interest and borrow fees add to the excitement, with the community debating the impact of potential dilution and the timing of news releases, as well as the possibility of a short squeeze. Despite some volatility, many investors express confidence in the long-term potential, urging others to hold firm.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million stock purchase agreement, sparking discussions of a potential short squeeze and comparisons to other high-flying stocks. Community members are actively debating the impact of this agreement and anticipating upcoming news from an investor summit. Some traders are expressing concerns about dilution, while others remain optimistic about the company's long-term potential in the glucose monitoring market.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape ($QS) is trending as community members discuss the implications of its battery tech being demoed in a Ducati motorcycle at IAA Mobility. Investors are weighing positive developments, including potential partnerships, against concerns about timeline to revenue and cash burn. Discussions also involve speculation around potential OEM partners and the impact of solid-state battery technology on the broader EV market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +5.75% and +3.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts sharply upgraded their outlook on Nektar Therapeutics on Wednesday following positive topline results from the company’s Phase 2b REZOLVE-AD trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.Nektar Therapeutics’ stock closed Wednesday up 19.1% at $29.12 and added another 1.1% after hours to $29.43.Jefferies lifted its price target from $2 to $69, citing improved confidence in rezpegaldesleukin’s efficacy and safety in what it described as an “enormous disease space.”&nbsp;The firm maintained a ‘Buy’ rating.Additionally, BTIG raised its target to $100 from $60, calling the stock a “pound the table BUY” and noting that all three dose arms achieved statistical significance across primary and secondary endpoints at 16 weeks.&nbsp;BTIG analysts said the “robust” data support rezpegaldesleukin’s status as a novel mechanism of action with&nbsp;the potential to outperform current therapies.Meanwhile, H.C. Wainwright was the most bullish, increasing its target from $6.50 to $120 and calling the results “paradigm-shifting.”&nbsp;The firm said rezpeg’s highly differentiated profile could reshape the atopic dermatitis treatment landscape and noted further improvement may come in the 36-week maintenance data expected in Q1 2026.Nektar said its primary 16-week induction data&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nektar-therapeutics-announces-positive-data-from-eczema-drug-in-mid-stage-trial/chm40c0RR3i">met its primary endpoint</a>, with a statistically significant improvement in Eczema Area and Severity Index (EASI) in all dose arms versus placebo.&nbsp;The company also met its secondary endpoints, which include EASI-75, EASI-50, BSA score, vIGA-AD 0/1, Itch NRS, and EASI-90 at the highest dose.&nbsp;Safety was consistent with previous data, and&nbsp;blood biomarker data showed strong on-target, dose-dependent activity.The results will be shared at a medical conference later in 2025. The company expects to report Phase 2b data for rezpeg in alopecia areata in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said that Nektar could touch $100 as early as tomorrow.&nbsp;<stembedurl>https://stocktwits.com/LFG2030/message/619030106</stembedurl>Another speculated that, barring an immediate equity offering, the stock might reach $40 in the next session.<stembedurl>https://stocktwits.com/Majlo/message/619029852</stembedurl>Others remained cautious, noting&nbsp;that dilutive financings often follow such rallies.&nbsp;One user said an offering was likely “incoming,” potentially in the $15 range.<stembedurl>https://stocktwits.com/BIGPHILLY/message/619028491</stembedurl>Still, some bulls pushed back, dismissing near-term offering concerns as "bear hopium" and predicting a move to $49 to fill the gap, with all-time highs (ATH) as the next target.<stembedurl>https://stocktwits.com/Da_Closer/message/619027710</stembedurl>Nektar’s stock has doubled its value so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis. 

Equity

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.nektar.com/news-releases/news-release-details/rezolve-ad-phase-2b-study-rezpegaldesleukin-meets-primary-and">announced</a> that its mid-stage study evaluating Rezpegaldesleukin in atopic dermatitis demonstrated improvement in area affected and severity.The global Phase 2b study is being conducted in 393 patients with moderate-to-severe atopic dermatitis. The company announced that, at week 16, patients who received Rezpegaldesleukin showed improvement in eczema area and severity score from baseline, as compared to placebo, using a widely used index.The trial also demonstrated that Rezpegaldesleukin reduced disease severity by as much as 90% or more with higher doses of the drug.Atopic dermatitis is the most common type of eczema, affecting approximately 30 million people in the U.S., according to Nektar. It is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inﬂammation.Rezpegaldesleukin is an investigational therapy that may address the underlying immune system imbalance in people with many autoimmune and inflammatory conditions.It targets the interleukin-2 receptor complex in the body to stimulate the proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, Rezpegaldesleukin aims to restore the immune system's balance.The company is now looking forward to reporting results from its trial of Rezpegaldesleukin in alopecia areata, an autoimmune disease that causes hair loss, in the fourth quarter of this year.Following the update from the company, H.C. Wainwright raised the firm's price target on Nektar to $120 from $6.50 while keeping a ‘Buy’ rating on the shares.On Stocktwits, retail sentiment around Nektar jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_04_09_PM_png_6458c1b61c.webp" alt="NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits" width="628" height="66"><figcaption>NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the user to jump as much as 150% later today.<stembedurl>https://stocktwits.com/US_Bull/message/618826543</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up by 66% this year and by about 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-tells-congress-fed-can-wait-on-rate-cuts-despite-pressure-from-trump/chm4hMMRR3h">Jerome Powell Tells Congress Fed Is ‘Well Positioned To Wait’ On Rate Cuts Despite Mounting Pressure From Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further

Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.

Nektar Therapeutics shares jumped 35.3% in&nbsp;extended trading Monday after the company said it&nbsp;would release topline results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for atopic dermatitis on Tuesday.The stock closed Monday’s regular session up 12.1% at $9.54.The experimental treatment is called NKTR-358 or REZPEG. It's a first-in-class regulatory T-cell (Treg) stimulator in development for autoimmune and inflammatory skin diseases.Nektar will hold an investor webcast at 8:15 a.m. ET on June 24 to discuss the 16-week induction data from the global trial.The stock reaction follows CEO Howard Robin's remarks in May that the company was on track to deliver trial results in June, positioning rezpegaldesleukin to emerge as an “important novel mechanism” to treat patients with chronic autoimmune disorders.The company also reiterated that topline data from a separate Phase 2 trial in alopecia areata are expected by December.In its most recent earnings report, Nektar posted a Q1 adjusted loss of&nbsp;$0.22 per share, wider than the consensus estimate of&nbsp;$0.19 loss per share. Revenue came in at $10.5 million, below analysts' expectations of $15.36 million.Robin also said Nektar is advancing other pipeline assets, including NKTR-0165 for multiple sclerosis and ulcerative colitis and a bispecific antibody candidate, NKTR-0166, both targeting the TNFR2 receptor.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,600% surge in 24-hour message volume.One user expects shares of Nektar to climb to the $14–$15 range overnight.&nbsp;<stembedurl>https://stocktwits.com/RealBobbyAxelrod/message/618755635</stembedurl>Another user noted the strong after-hours move likely reflected optimism, but expressed uncertainty about holding the position, saying they were tempted to take some profits.<stembedurl>https://stocktwits.com/Patrick2343/message/618743686</stembedurl>The stock has declined 33.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, a biopharmaceutical company located on 3rd Street, in the Mission Bay District of San Francisco, California, October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTR Nektar Therapeutics